IDXX — IDEXX LABORATORIES INC /DE
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 874716 ·
Last close
$541.31
Market Cap
$42.70B
52W High
$605.82
52W Low
$523.38
ADV30
647,442
Next earnings
2026-08-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,140,820,000 | 722,739,000 | 362,586,000 | 278,446,000 | 3,385,497,000 | 200,528,000 | 1,829,394,000 |
| Dec 2025 | 1,090,579,000 | 658,114,000 | 315,605,000 | 248,188,000 | 3,350,759,000 | 180,070,000 | 1,745,376,000 |
| Sep 2025 | 1,105,239,000 | 683,354,000 | 354,846,000 | 274,610,000 | 3,386,712,000 | 208,166,000 | 1,825,526,000 |
| Jun 2025 | 1,109,457,000 | 694,732,000 | 373,046,000 | 293,989,000 | 3,330,794,000 | 164,594,000 | 1,871,967,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,210,091,000
Investing CF
$-140,173,000
Financing CF
$-1,046,073,000
CapEx
$-141,984,000
Dividends Paid
—
Buybacks
$-1,167,110,000
EPS Diluted TTM
$13.58
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$6,670,348,000
Inventory
$382,400,000
Receivables
$697,212,000
ST Investments
—
EBIT TTM
$1,408,474,000
Pretax Income TTM
$1,369,547,000
Interest Exp TTM
$38,927,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,446,094,848
EBITDA
$1,545,885,952
Free Cash Flow
$786,844,480
Enterprise Value
$43,605,078,016
Total Cash
$200,528,000
Total Debt
$1,105,451,008
Shares Out
78,882,997
Trailing EPS
$13.59
Book Value
$19.64
ROE
72.9%
ROA
26.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,303,702,000 | 1,360,031,000 | 1,059,464,000 | 3,350,759,000 | 1,745,376,000 | — | 1,181,805,000 |
| Dec 2024 | 3,897,504,000 | 1,128,337,000 | 887,867,000 | 3,293,443,000 | 1,698,130,000 | — | 929,001,000 |
| Dec 2023 | 3,660,953,000 | 1,097,128,000 | 845,042,000 | 3,259,925,000 | 1,775,395,000 | — | 906,510,000 |
| Dec 2022 | 3,367,324,000 | 898,765,000 | 679,089,000 | 2,746,765,000 | 2,138,028,000 | — | 542,984,000 |
TTM Snapshot
Revenues TTM
$3,543,152,000
NetIncome TTM
$801,245,000
OpCashFlow TTM
$0
Assets (Latest)
$3,293,443,000
Forward EPS
$16.52
Max Pain — expiry 2026-07-17
max pain strike: $570.00 · spot: $551.90 · call oi: 909 · put oi: 406
Expected Move to 2026-07-17:
±$35.20
(6.38%) —
implied range
$516.70 –
$587.10
· ATM straddle on $550.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $28.59B | $171.28 | — |
| INCY | INCYTE CORP | $20.86B | $104.40 | — |
| MEDP | Medpace Holdings, Inc. | $13.52B | $473.48 | — |
| ICLR | ICON PLC | $10.92B | $142.67 | — |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $8.99B | $186.60 | — |
News headlines (Yahoo Finance, 1h cache)
A Small Upgrade Could Have a Big Impact for IDEXX Customers
2026-06-22 13:31 · Yahoo
Is IDEXX Laboratories Stock Underperforming the Nasdaq?
2026-06-09 12:42 · Yahoo
Idexx (IDXX) Down 3.2% Since Last Earnings Report: Can It Rebound?
2026-06-04 15:30 · Yahoo
IDEXX Parasite Test Expansion Links Zoonotic Risk And Valuation Debate
2026-06-03 21:19 · Yahoo
IDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conference
2026-05-30 11:02 · Yahoo
IDEXX Laboratories (IDXX) Embeds an Early Kidney Disease Detector Into Its Most Popular Test Profile
2026-05-27 21:56 · Yahoo
Is Wall Street Bullish or Bearish on IDEXX Laboratories Stock?
2026-05-26 12:05 · Yahoo
IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
2026-05-26 11:00 · Yahoo
Should IDEXX’s (IDXX) SDMA-Enhanced Catalyst Panels Prompt Action From Long-Term Diagnostics Investors?
2026-05-20 12:06 · Yahoo
IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
2026-05-19 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.